Ahlskog JE - Search Results

1

Risk tables for parkinsonism and Parkinson's disease.

Elbaz A, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA. Elbaz A, et al. Among authors: ahlskog je. J Clin Epidemiol. 2002 Jan;55(1):25-31. doi: 10.1016/s0895-4356(01)00425-5. J Clin Epidemiol. 2002. PMID: 11781119

2

Movement disorders as sequelae of central pontine myelinolysis: report of three cases.

Maraganore DM, Folger WN, Swanson JW, Ahlskog JE. Maraganore DM, et al. Among authors: ahlskog je. Mov Disord. 1992;7(2):142-8. doi: 10.1002/mds.870070208. Mov Disord. 1992. PMID: 1584236 Review.

3

Guamanian neurodegenerative disease: investigation of the calcium metabolism/heavy metal hypothesis.

Ahlskog JE, Waring SC, Kurland LT, Petersen RC, Moyer TP, Harmsen WS, Maraganore DM, O'Brien PC, Esteban-Santillan C, Bush V. Ahlskog JE, et al. Neurology. 1995 Jul;45(7):1340-4. doi: 10.1212/wnl.45.7.1340. Neurology. 1995. PMID: 7617195

4

Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria.

Collins SJ, Ahlskog JE, Parisi JE, Maraganore DM. Collins SJ, et al. Among authors: ahlskog je. J Neurol Neurosurg Psychiatry. 1995 Feb;58(2):167-73. doi: 10.1136/jnnp.58.2.167. J Neurol Neurosurg Psychiatry. 1995. PMID: 7876846 Free PMC article.

5

Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline.

Ahlskog JE, Muenter MD, Maraganore DM, Matsumoto JY, Lieberman A, Wright KF, Wheeler K. Ahlskog JE, et al. Arch Neurol. 1994 Dec;51(12):1236-41. doi: 10.1001/archneur.1994.00540240080020. Arch Neurol. 1994. PMID: 7986180 Clinical Trial.

6

Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa.

Lieberman A, Imke S, Muenter M, Wheeler K, Ahlskog JE, Matsumoto JY, Maraganore DM, Wright KF, Schoenfelder J. Lieberman A, et al. Among authors: ahlskog je. Neurology. 1993 Oct;43(10):1981-4. doi: 10.1212/wnl.43.10.1981. Neurology. 1993. PMID: 8105422 Clinical Trial.

7

Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project.

Uitti RJ, Ahlskog JE, Maraganore DM, Muenter MD, Atkinson EJ, Cha RH, O'Brien PC. Uitti RJ, et al. Among authors: ahlskog je. Neurology. 1993 Oct;43(10):1918-26. doi: 10.1212/wnl.43.10.1918. Neurology. 1993. PMID: 8413948

8

Amantadine treatment is an independent predictor of improved survival in Parkinson's disease.

Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Ho MM, Prasad M, Rajput A, Basran P. Uitti RJ, et al. Among authors: ahlskog je. Neurology. 1996 Jun;46(6):1551-6. doi: 10.1212/wnl.46.6.1551. Neurology. 1996. PMID: 8649547

9

Does levodopa therapy delay death in Parkinson's disease?

Uitti RJ, Ahlskog JE, Maraganore DM. Uitti RJ, et al. Among authors: ahlskog je. Mov Disord. 1996 May;11(3):343-4. Mov Disord. 1996. PMID: 8723162 No abstract available.

10

Intranasal apomorphine rescue therapy for parkinsonian "off" periods.

Dewey RB Jr, Maraganore DM, Ahlskog JE, Matsumoto JY. Dewey RB Jr, et al. Among authors: ahlskog je. Clin Neuropharmacol. 1996 Jun;19(3):193-201. doi: 10.1097/00002826-199619030-00001. Clin Neuropharmacol. 1996. PMID: 8726538 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

292 results

Search Page

Filters